- CME/CE Activities
- Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201000006G from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Summary of AHRQ's Update to the Comparative Effectiveness Review of Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
To Receive a Certificate for This Activity:
Activity DescriptionOsteoporosis is a prevalent systemic skeletal disease of bone deterioration and loss of mass resulting in chronic pain and disability. It is common in postmenopausal women but men are also at risk for bone fractures associated with low bone density. In 2011, the Agency for Healthcare Research and Quality (AHRQ) conducted an updated review on effectiveness and safety of treatments for osteoporosis, including new therapies for the prevention of vertebral and nonvertebral fractures in women and men. The review examined factors affecting diagnosis, treatment adherence, and the efficacy and adverse effects of monitoring and long-term treatment. This monograph recaps the key findings from this review, allowing healthcare decisionmakers to gain insight into the efficacy and safety of therapies used to prevent vertebral and non vertebral fractures, as well as the effects of risk factors, adherence, bone density monitoring, and long-term therapy on patient outcomes. In addition, applications to practice of the AHRQ findings are discussed to empower clinicians with the knowledge needed to provide evidence-based care for their patients.
At the conclusion of this activity, the participant should be able to:
- Compare the benefits and harms of treatments for bone fracture reduction, and assess the impact of risk factors in subpopulations on efficacy
- Examine the prevalence rates, barriers to treatment, and consequences of adherence and persistence on efficacy
- Evaluate the effects of bone mineral density monitoring, and long-term therapy on patient outcomes
- Apply the review findings to making effective, patient-centered treatment and management decisions in the prevention of bone fractures
This CME activity is designed to meet the educational needs of physicians, pharmacists, nurses, and case managers.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
June 15, 2012 through September 30, 2013. Original release date: June 15, 2012
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Silvina Levis, MD
Director, Osteoporosis Center
Professor of Medicine
University of Miami Miller School of Medicine
Director of Clinical Protocol Development
Geriatric Research, Education, and Clinical Center (GRECC)
Miami VA Medical Center
George Theodore, PhD
Medical Education Researcher
PRIME Education, Inc.
Heidi Wynn Maloni, PhD, ANP-BC
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Michele B Kaufman, PharmD, BPharm, RPh
PRN Communications, Inc
New York Downtown Hospital
New York, NY
Richard K Mastrole, MD
Internal Medicine and Rheumatology
Holy Cross Medical Group
Ft Lauderdale, FL
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Adjunct Faculty & Preceptor
Albany College of Pharmacy
Kathleen A Jarvis, MS, RN, CCM
Fort Lauderdale, FL
Physician Credit Designation Statement
PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
PRIME® designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is 0255-0000-12-022-H01-P. This learning activity is Knowledge-Based.
Nurse Accreditation Statement
PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
PRIME® designates this activity for 1.0 contact hour.
Case Manager Accreditation Statement
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|Silvina Levis, MD
|George Theodore, PhD
|Heidi Wynn Maloni, PhD, ANP-BC
|Michele B Kaufman, PharmD, BPharm, RPh
|Richard K Mastrole, MD
|Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
|Kathleen A Jarvis, MS, RN, CCM
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
To access the activity, please complete this brief Pretest.
Post-Test & Evaluation
You must access the activity before receiving credit!
Clinician & Consumer Summaries on Osteoporotic Fractures
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.